Cellix Ltd

Contact Details

Skip to Navigation | Skip to Content | Skip to Login

Cellix Ltd
Unit 3.81
Institute of Molecular Medicine
Trinity Centre for Health Sciences
James St., Dublin 8
Ireland
CRO no.392272

Phone: +353 1 896 2799
Fax: +353 1 896 2771
Email: info@cellixltd.com

Start of page content

Home >> Therapeutic Areas >> Respiratory >> Asthma

Therapeutic Areas

Asthma

Characterising additional anti-inflammatory effects of the anti-asthma drug, Montelukast.

Cellix's VenaFlux^TM platform and Vena8^TM Biochips were used to determine novel anti-inflammatory effects of montelukast on resting and GM-CSF stimulated eosinophils. New drug targets were identified through eosinophil adhesion to endothelial cell markers.

Download Asthma Application Note (R100).

Inflammation - Asthma / COPD: Eosinophil Adhesion to HMVEC-L at 0.5 dyne/cm²